Emerging Drug Developer: Argos Therapeutics
Immunology is a hot topic in biotechnology these days, and Argos Therapeutics is gambling on its dendritic cell technology to get it past Phase II and into a new stage of development. With a drug platform aimed at cancer and infectious diseases, the Durham, NC-based developer is touting some early successes and some great expectations for the next two years. It's already managed to win over some of the leading names in global biotechnology as partners. And data due by mid-2009 will be crucial to its long-term success. Article